Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GPX4 | P36969 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24602602 | 0.91 | LMNA (0.41) | ALDH1A1NPC1TP53GPX4RAB9A | |
| SCHEMBL24602625 | 0.91 | NPC1 (0.32) | ALDH1A1NPC1TP53GPX4RAB9A | |
| SCHEMBL24259294 | 0.87 | MLYCD (0.37) | ALDH1A1NPC1TP53GPX4RAB9A | |
| SCHEMBL24259121 | 0.86 | ALDH1A1 (0.36) | ALDH1A1NPC1TP53GPX4RAB9A | |
| SCHEMBL24602563 | 0.78 | POLB (0.31) | ALDH1A1NPC1TP53GPX4RAB9A | |
| SCHEMBL24259047 | 0.78 | RXRA (0.39) | ALDH1A1MTNR1AMTNR1BLMNAMAPT | |
| SCHEMBL24259504 | 0.77 | MAPT (0.33) | ALDH1A1LMNAMAPT | |
| SCHEMBL24259162 | 0.77 | NPC1 (0.32) | ALDH1A1NPC1TP53GPX4RAB9A | |
| SCHEMBL24258809 | 0.76 | RAD52 (0.35) | ALDH1A1MTNR1AMTNR1BLMNAMAPT | |
| SCHEMBL22353967 | 0.75 | NR1H4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | ALDH1A1 3573/4885NPC1 290/4885TP53 1486/4885 |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | ALDH1A1 3573/4885NPC1 290/4885TP53 1486/4885 |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | ALDH1A1 2862/4885NPC1 149/4885TP53 1398/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | ALDH1A1 2862/4885NPC1 149/4885TP53 1398/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | ALDH1A1 2862/4885NPC1 149/4885TP53 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.